WHAT IS BINGE EATING DISORDER?
Binge eating disorder (BED) is characterized by recurrent episodes of binge eating. A binge eating episode consists of consuming an excessive amount of food within a discrete period of time (e.g., within any 2-hour period) accompanied by a sense of loss of control over the eating. Binge eating is also not associated with the regular use of weight-compensatory behaviors (like making oneself sick, fasting, or over-exercising).1 Many adults with BED report having symptoms of BED for a long period of time, however less than half of these cases are recognized in the healthcare community.2
HOW CAN I TELL IF I AM BINGE EATING?
Binge eating episodes are usually characterized by three or more of the following:
– Eating much more rapidly than normal
– Eating until feeling uncomfortably full
– Eating large amounts of food when not feeling physically hungry
– Eating alone because of feeling embarrassed by how much one is eating
– Feeling disgusted with oneself, depressed, or very guilty afterwards 1
[1] American Psychiatric Association. DSM-5-Eating Disorders. Updated 2013. Accessed January 26, 2021. www.psychiatry.org/psychiatrists/practice/dsm[2] Keski-Rahkonen, Anna. “Epidemiology of binge eating disorder: prevalence, course, comorbidity, and risk factors.” Current opinion in psychiatry 34.6 (2021): 525-531
ABOUT THIS STUDY
This study is evaluating an oral investigational medication (solriamfetol) in adults with BED. Solriamfetol is approved by the FDA for people who have excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea (OSA), which are sleep-related disorders. Solriamfetol is an investigational treatment for BED, meaning it has not yet been approved by any health authority for the treatment of BED.
Qualified participants will receive study-related care and evaluations at no cost. Each participant’s BED and overall health will be monitored by a team of physicians and study staff. Compensation for your time and travel may be available.
WHY PARTICIPATE?
Clinical research participation is an important part of developing new treatments. To assess the safety and effectiveness of new drugs, research requires people like you.
Participation in a clinical research study is completely voluntary, and you may withdraw from a clinical research study at any time for any reason. To learn more about this research study and find a research center near you, visit clinicaltrials.gov/study/NCT06413433
BINGE EATING DISORDER BY THE NUMBERS
Binge eating disorder was relatively lesser known than other forms of disordered eating until 2013.
By 2030 it is estimated that around half a million US men and 1.5 million US women will have binge eating disorder 1.
94% of people with binge eating disorder report having a comorbid mental health problem 2.
60% of adults with binge eating disorder are not sure whether they need to receive help 3.
1. STRIPED Harvard. 2020. Report: Economic Costs Of Eating Disorders. https://www.hsph.harvard.edu/striped/report-economic-costs-of-eating-disorders
2. Keski-Rahkonen, Anna. “Epidemiology of binge eating disorder: prevalence, course, comorbidity, and risk factors.” Current opinion in psychiatry 34.6 (2021): 525-5313. Linardon, J., Rosato, J., & Messer, M. (2020). Break Binge Eating: Reach, engagement, and user profile of an Internet-based psychoeducational and self-help platform for eating disorders. International Journal of Eating Disorders, 53, 1719-1728
AM I ELIGIBLE?
If you’re living with Binge Eating Disorder, you may be eligible for the ENGAGE study.
The ENGAGE study is looking for adults who:*
- Are 18-55 years old
- Currently experience symptoms of Binge Eating Disorder (BED) including recurrent episodes of consuming excessive amounts of food accompanied by a sense of loss of control over the eating
- Experience at least 2 binge eating episodes per week for the last 6 months (see inside)
*Additional eligibility criteria apply
If you meet these criteria, the ENGAGE study may be of interest to you.
To learn more and see if you may be eligible, visit: clinicaltrials.gov/study/NCT06413433
AXSOME and its logo are registered trademarks of Axsome Therapeutics, Inc. © 2024 Axsome Therapeutics, Inc. All rights reserved.
